Hypoxia in tumors: Molecular targets for anti-cancer therapeutics

Advances in Enzyme Regulation

Volumn 44, Issue 1, 2004, Pages 93-108

  Williams, Kaye J ^a   Cowen, Rachel L ^a   Brown, Louisa M ^a   Chinje, Edwin C ^a   Jaffar, Mohammed ^a   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL; ANOXIA; CONFERENCE PAPER; DRUG DESIGN; HUMAN; MOUSE; NEOPLASM; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG DESIGN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASMS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 9644262863     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2003.11.019     Document Type: Conference Paper

References (62)

1. Achison M., Hupp T.R. Hypoxia attenuates the p53 response to cellular damage. Oncogene. 22:2003;3431-3440
2. 2-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α). J Cancer Res Clin Oncol. 128:2002;358-362
3. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early stage invasive cervical cancer. Cancer Res. 60:2000;4693-4696
4. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 93:2001;309-314
5. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res. 56:1996;941-943
6. Brown L.M., Williams K.J., Cowen R.L., Melillo G., Sausville E., Stratford I.J. The potential therapeutic application of targeting HIF-1 using gene therapy or small molecule approaches. Proc AACR. 44:2003;4633
7. Bruick R.K. Expression of the gene encoding the proapoptotic NIP3 protein is induced by hypoxia. Proc Natl Acad Sci USA. 97:2000;9082-9087
8. Carmeliet P., Dor Y., Herbert J.-.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P.J., Moons L., Jain R.K., Collen D., Keshet E. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394:1998;485-490
9. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 276:2001;9519-9525
10. Chen J., Zhao S., Nakada K., Kuge Y., Tamaki N., Okada F., Wang J., Shindo M., Higashino F., Takeda K., Asaka M., Katoh H., Sugiyama T., Hosokawa M., Kobayashi M. Dominant-negative hypoxia-inducible factor 1 alpha reduces the tumorigenecity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 162:2003;1283-1291
11. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:2002;3387-3394
12. Cowen R.L., Williams K.J., Jaffar M., Telfer B., Garvey D., Stratford I.J. A novel human P450 reductase activated indolequinone prodrug for use in adenoviral mediated hypoxia selective gene therapy. Eur J Cancer. 38(S7):2002;492
13. Cowen RL, Patterson AV, Telfer BA, Airley R, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of Mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2003;2:901-9.
14. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard F, Telfer BA, Wind NS, Stratford IJ. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumour radio-resistance and effecting cure. Cancer Res 2004;64:1396-402.
15. Dachs G.U., Patterson A.V., Firth J.D., Ratcliffe P.J., Townsend K.M., Stratford I.J., Harris A.L. Targeting gene expression to hypoxic tumor cells. Nature Med. 3:1997;515-520
16. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinksy M., Wouters B., Wilson C., Miller C., Demonacos C., Stratford I.J., Dive C. Hypoxia mediated down regulation of Bid and Bax in tumours occurs via HIF-1 dependent and independent mechanisms and contributes to drug resistance. Mol Cell Biol. 24:2004;2875-2889
17. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., Hill R.P. Oxygenation predicts radiation response in patients with cervix cancer. Radiother Oncol. 48:1998;149-156
18. Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., Broder G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 14:1988;831-838
19. Giaccia AJ, Koumenis C, Denko N. The influence of tumor hypoxia on malignant progression. Tumor hypoxia: Pathophysiology, clinical significance and therapeutic perspectives. Vaupel and Kelleher, editors. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1999. p. 115-24.
20. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch S.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91
21. Griffiths J.R., McSheehy P.M.J., Robinson S.P., Troy H., Chung Y.-.L., Leek R.D., Williams K.J., Stratford I.J., Harris A.L., Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1β HIF- 1β 1. evidence of an anabolic role for the HIF-1 pathway Cancer Res. 62:2002;688-695
22. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515
23. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., Stratford I.J., Gassmann M., Desbailetts I. Rescue of hypoxia-inducible factor-1α- deficient tumor growth by wild-type cells is independent of the vascular endothelial growth factor. Cancer Res. 62:2002;2962-2970
24. 2 sensing Science. 292:2001;464-468
25. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472
26. Jiang B.-.H., Agani F., Passaniti A., Semenza G.L. V-src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding VEGF and enolase 1. involvement of HIF-1 in tumor progression Cancer Res. 57:1997;5328-5335
27. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., LaRusch J., Pak B., Taghavi P., Semenza G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63:2003;1138-1143
28. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med. 6:2000;1335-1340
29. Lando D., Gorman J.J., Whitelaw M.L., Peet D.J. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem. 270:2003;781-790
30. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis. novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol Cell Biol. 21:2001;3995-4004
31. Mahon P.C., Hirota K., Semenza G.L. FIH-1. a novel protein that interacts with hif-1α and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev. 15:2001;2675-2686
32. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 94:1997;8104-8109
33. Maxwell P.H., Wiesener M.S., Chang G.-.W., Clifford S.C., Vaux E.C., Cockman M.E., Wycoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumur suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
34. Narravula S., Colgan S.P. Hypoxia-inducible factor 1-mediated inhibition of peroisome proliferator-activated receptor α expression during hypoxia. J Immunol. 166:2001;7543-7548
35. Nordsmark M., Overgaard J. A confirmatory prognostic study on oxygenation status and regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 57:2000;39-43
36. Okunieff P., Hoeckel M., Dunphy E.P., Schlenger K., Knoop C., Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 26:1993;631-636
37. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., Stratford I.J. Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer. 72:1995;1144-1150
38. Patterson A.V., Saunders M., Chinje E.C., Talbot D.C., Harris A.L., Stratford I.J. Overexpression of human NADPH. cytochrome c (p450) reductase confers enhanced sensitivity to both tirapazamine (sr4233) and rsu1069 Br J Cancer. 76:1997;1338-1347
39. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., van der Kogel A.J., Wolf C.R., Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumors. Gene Ther. 9:2002;946-954
40. Raleigh J.A., Chou S.C., Arteel G.E., Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 151:1999;580-589
41. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:2002;4316-4324
42. Ravi R., Mookerjee B., Bhujwalla Z.M., Hayes Sutter C., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α Genes Dev. 14:2000;34-44
43. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. P42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem. 274:1999;32631-32637
44. Ryan H.E., Lo J., Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularisation. EMBO J. 17:1998;3005-3015
45. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015
46. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V. Caro Jaime. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem. 278:2003;14013-14019
47. Siim B., Menke D.R., Dorie M.J., Brown J.M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors. relationship to tumor hypoxia Cancer Res. 57:1997;2922-2928
48. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1 dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:2001;6669-6673
49. Stratford IJ, Patterson AV, Dachs GU, Telfer B, Williams KJ. Hypoxia-mediated gene expression Tumor Hypoxia: Pathophysiology, clinical significance and therapeutic perspectives. Vaupel and Kelleher editors. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. 1999. p. 107-13.
50. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., Krissansen G.W. Gene transfer of antisense hypoxia-inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8:2000;638-645
51. Teicher B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41:1981;73-81
52. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 13:1994;39-68
53. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., Wenger R.H. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene. 22:2003;3213-3220
54. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., Petrat K., Putz V., Hescheler J., Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB. 17:2003;503-505
55. Williams K.J., Telfer B.A., Airley R.E., Peters H.P., Sheridan M.R., van der Kogel A.J., Harris A.L., Stratford I.J. A protective role for HIF-1 in response to redox manipulation and glucose deprivation. implications for tumorigenesis Oncogene. 21:2002;282-290
56. Wood S.M., Gleadle J.M., Pugh C.W., Hankinson O., Ratcliffe P.J. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. J Biol Chem. 271:1996;15117-15123
57. Wood S.M., Wiesener M.S., Yeates K.M., Okada N., Pugh C.W., Maxwell P.H., Ratcliffe P.J. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1α-subunit (HIF-1α). J Biol Chem. 273:1998;8360-8368
58. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., Embleton J., Newell D., Raymond R., Stables J., Stephens T., Wallace J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 77:1998;1-10
59. Yeo E.-.J., Chun Y.-.S., Cho Y.-.S., Kim J., Lee J.-.C., Kim M.-.S., Park J.-.W. YC-1. a potential anticancer drug targeting hypoxia-inducible factor 1 J Natl Cancer Inst. 95:2003;516-525
60. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA. 85:1988;9533-9537
61. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
62. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 15:2000;391-396